Tag: the war on (some) drugs

LSD And Psilocybin Could Be Powerful Treatments For Pain—Without Opioids’ Dwindling Effects Over Time, Study Says

LSD and psilocybin could offer promising therapeutic potential for the treatment of chronic pain “on a mechanistic and experiential level,” according to a newly published literature review that highlights scientific findings happening as part of the “psychedelic renaissance”—a recent thawing of stigma and opposition into psychedelics research after decades of prohibition.

What’s more, authors note, the pain-relieving effects of LSD and psilocybin seem to increase with repeated treatment, unlike opioids, which display “decreased therapeutic effect” over time.

The narrative review, published last month in the South African Medical Journal, charts both the history of the two substances as well as scientists’ emerging understanding of their methods of action. It notes that the drugs seem not just to reduce pain but also better manage the experience of pain.

“Recent neuroimaging studies combined with small sample interventions with classic psychedelic agents,” authors wrote, “may point towards a possible means of improving the treatment of chronic pain on a mechanistic and experiential level.”

Classic psychedelics, the literature review explains, are those that bind to the central nervous system’s 5-HT2A receptors. They include both LSD and psilocybin.

The way psilocybin binds to receptors in the central nervous system “has similar effects to LSD on cognition, emotional processing, self-awareness and the perception of pain,” says the literature review, “which underpins its potential therapeutic benefit in treating people suffering with pain. Numerous small trials of LSD and psilocybin for chronic pain have already shown a good safety profile, with minimal physical dependence, withdrawal syndrome, or compulsive drug seeking compared with other analgesic agents.”

While the two drugs are part of the same family of alkaloids, their history is, of course, much different. The review describes explains that LSD was first synthesized in 1938, meaning humans have used it for less than a century. Psilocybin’s use stretches back thousands of years. In the modern U.S., psilocybin use was popularized in the late 1950s, while LSD grew to prominence in the ’60s and ’70s.

While there have been no reports of direct mortality from either substance and no withdrawal following chronic use, the study says, “the use of psilocybin in clinical research ended at the same time as LSD research as the Controlled Substances Act was enforced.”

Associations with counterculture and anti-government sentiment meant LSD and psilocybin research was abandoned, authors wrote. “From 1977 until the early 2000s, no more LSD research was published, despite overwhelming evidence pointing towards therapeutic benefit.”

Prior research had indicated LSD might be useful in treating depression, pain, and physical suffering in cancer patients and others. Among seven patients with phantom limb pain, participants treated with LSD reduced their analgesic requirements, and two patients’ pain was resolved.

During what the review refers to as the modern “psychedelic renaissance” or “the new wave of psychedelic research,” studies have found that psilocybin or LSD may help reduce cluster headaches, end-of-life depression in cancer patients and chronic pain.

In a pain study, a small sample of patients who self-medicate with the psychedelics “revealed a decrease in the experience of pain during the psychedelic session and for up to 5 days after treatment, before their pain returned to baseline.”

“The most exciting revelation from these interviews relates to the lasting psychological and emotional effect the psychedelics had on those interviewed,” the review says. “They describe increased resilience, body-self-awareness and psychological flexibility and psychological flexibility, which led to feelings of acceptance, agency and hope.”

Keep reading

Medical Marijuana Growers And Caregivers Can Own Guns, But Patients Can’t, FBI Says In Little-Noticed Memo

Being a state-registered medical marijuana caregiver or grower doesn’t automatically disqualify a person from owning a firearm, the FBI says. But merely possessing a medical cannabis card as a patient does render a person ineligible.

Amid the growing tension between federal gun policies and the ever-expanding state marijuana legalization movement, a little-noticed FBI memo from 2019 offers a lens into the byzantine legal interpretations surrounding cannabis and firearms—an issue that’s recently been raised in multiple federal court cases.

The government has several different ways it assesses firearm eligibility in the context of cannabis, according to the memo from FBI’s Criminal Justice Information Services (CJIS) Division, which was briefly noted in a report from The New York Times last week. In some cases, that involves affirmatively restricting gun rights based on activities or documentation that doesn’t necessarily mean a person is an active marijuana consumer.

At their core, the federal rules say that being an “unlawful user” of a controlled substance, including marijuana, means a person cannot buy or possess a gun. Would-be gun purchasers are required to disclose such use as part of a Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) form before making a purchase, and lying on that form is a felony offense.

The statute behind that prohibition has been challenged in a number of federal courts over the past couple of years, with more than one judicial body determining that the restriction is unconstitutional. The Department of Justice (DOJ) has steadfastly defended the ban, however, contending that medical marijuana patients and everyday consumers pose unique dangers to society that justify withholding Second Amendment rights.

But the federal government’s interpretation of the policy is apparently more nuanced, as evidenced by the memo from CJIS’s National Instant Criminal Background Check System Section that’s gone largely unscrutinized since being published more than four years ago.

A person’s firearm eligibility is partly determined by whether their use of a controlled substance is deemed “current.” FBI says that’s “not limited to the use of drugs on a particular day, or within a matter of days or weeks before, but rather that the unlawful use has occurred recently enough to indicate the individual is actively engaged in such conduct.”

“ATF has determined that the present time is represented by the time frame of within the past 12 months,” the memo says.

Keep reading

Feds Release 250+ Pages Of Redacted Documents On Marijuana Rescheduling Recommendation, Detailing Cannabis’s Medical Value

More than three months after news leaked that the U.S. Health and Human Services Department (HHS) was recommending that marijuana be moved to Schedule III under the federal Controlled Substances Act (CSA), the agency has finally released a tranche of documents related to its recommendation and the detailed review it undertook on cannabis’s accepted medical value.

Among the materials newly made public are correspondence from HHS officials to Drug Enforcement Administration (DEA) Administrator Anne Milgram as well explanations of the health agency’s reasoning for the recommended change after conducting a required eight-factor analysis under the CSA. Most pages are heavily redacted, however, and some were withheld completely.

The documents were posted online Thursday by attorneys Shane Pennington and Matt Zorn, coauthors of the blog On Drugs. Zorn previously submitted a request under the Freedom of Information Act (FOIA) to obtain the records.

“We haven’t had a chance to wade through it all,” the two lawyers wrote, “but are putting it up here now and will follow up as soon as we’ve studied everything more deeply.”

In response to the FOIA request, HHS “reviewed 252 pages of records,” releasing just two pages in their entirety. Another 236 were redacted in part, while 14 pages were withheld completely. All the released documents are embedded at the end of this article.

Broadly, the documents outline new scientific information that’s come to light in recent years subsequent to an earlier denial of a rescheduling petition, which HHS suggests might now necessitate rescheduling marijuana.

“The current review is largely focused on modern scientific considerations on whether marijuana has a CAMU [currently accepted medical use] and on new epidemiological data related to the abuse of marijuana in the years since the 2015 HHS” evaluation of marijuana under the CSA’s eight-factor analysis.

HHS also notes that it “analyzed considerable data related to the abuse potential of marijuana,” but added that it’s a complicated consideration.

“Determining the abuse potential of a substance is complex with many dimensions,” HHS wrote, “and no single test or assessment provides a complete characterization. Thus, no single measure of abuse potential is ideal.”

Most subsequent pages of the document were withheld completely.

Keep reading

Ohio Senate Marijuana Bill Keeps Criminalization And Undermines Equity, Despite Expungements And Home Grow, Advocates Warn

Ohio’s voter-approved marijuana legalization law took effect on Thursday—but as lawmakers continue to push changes, advocates are calling attention to key provisions of a Senate-passed proposal that they say threatens to perpetuate criminalization and undermine social equity even while it walks back other significant alterations that were initially proposed such as a removal home cultivation rights.

At the same time, House lawmakers held a second hearing on Thursday about a separate measure to amend the legalization law.

After weeks of discussing revisions to the initiated statute, Republicans first unveiled legislation this week that would have done away with home grow, hiked marijuana taxes and re-criminalized possession of cannabis that wasn’t obtained from licensed retailers, which couldn’t open for at least one year. Some advocates were tentatively encouraged, therefore, when a significantly revised version with seeming improvements, including the restoration of home grow rights and addition of expungements provisions, was released and quickly advanced through the Senate with near-unanimous support on Wednesday.

But the brief discussion of the bill in committee prior to the full chamber vote—which also came amid House consideration of a separate GOP-led measure—did not adequately reflect the substantive changes that would be made to the law voters passed with 57 percent support, equity advocates say.

Keep reading

House And Senate Reach Deal To Require Psychedelics Clinical Trials For Active Duty Military Service Members Under Defense Bill

Bipartisan and bicameral congressional lawmakers have reached an agreement on a large-scale defense bill that contains a House GOP-led section to fund studies into the therapeutic use of psychedelics such as psilocybin and MDMA for military service members.

Following negotiations, lawmakers released the conference report for the 2024 National Defense Authorization Act (NDAA) on Wednesday evening, maintaining psychedelics research provisions championed by Rep. Morgan Luttrell (R-TX) that were attached to the House version over the summer. The report notes, however, that the House negotiators receded on a separate section to create a medical cannabis pilot program for veterans.

The psychedelics provisions that have been adopted would require the Department of Defense (DOD) to establish a process by which service members with post-traumatic stress disorder (PTSD) or traumatic brain injury could participate in clinical trials involving psilocybin, MDMA, ibogaine and 5-MeO-DMT. The list of covered psychedelics was also expanded to broadly include “qualified plant-based alternative therapies.”

DOD would need to facilitate that process within 180 days of enactment. It could partner with eligible federal or state government agencies, as well as academic institutions to carry out the clinical trials, with $10 million in funding.

Keep reading

Marijuana Is Now Legal In Ohio As Voter-Approved Law Takes Effect, But Lawmakers Are Considering Some Changes

Ohio’s voter-approved marijuana legalization initiative took effect on Thursday, and despite ongoing wrangling by state lawmakers to modify significant portions of the law, some provisions—including legal use, possession and home cultivation of cannabis—have immediate impacts.

Voters solidly approved the legalization ballot measure, Issue 2, on a 57–42 margin last month. But soon after, Republicans in the state Senate indicated their plans to gut the bill by eliminating home grow, reducing legal possession and allowable THC limits, raising sales tax, criminalizing the use and possession of marijuana obtained outside of a licensed retailer and steering funding away from social equity programs and toward law enforcement. Stakeholders said the overhaul would devastate the market, with ACLU of Ohio calling the measure a “demolition of Issue 2.”

As of Wednesday, however, the GOP-controlled Senate abruptly reversed course, and the full chamber instead approved a revised bill that in some ways would expand the voter-approved law. Among other changes, it would allow all adults 21 and older to buy cannabis from existing medical dispensaries in as soon as 90 days, maintain home cultivation rights and provide for automatic expungements of prior convictions.

The bill now goes to the House, where an alternative measure has been introduced. But regardless of how the proposed changes pan out, some reforms have already taken effect with Issue 2 kicking in on Thursday. Here’s a brief rundown of what’s new and what’s still to come in the months ahead.

Keep reading

Florida Medical Marijuana Company Asks Court To Block Legalization Initiative That Would ‘Significantly Impact’ Its Business And Patients

A Florida medical marijuana certification company is seeking to block an adult-use cannabis legalization ballot initiative in the state Supreme Court, arguing that the reform “disproportionately prioritizes” profits from recreational sales and that it would “significantly impact our business operations and the well-being of our clients.”

My Florida Green, a service that connects patients seeking medical cannabis cards to doctors who can certify them, is asking the court to allow it to submit an amicus curiae brief in the case contesting the Smart & Safe Florida legalization measure that was brought by state Attorney General Ashley Moody (R).

The company says that it’s not opposed to adult-use legalization in principle, but it’s arguing that there are “potential consequences” of the 2024 constitutional amendment that could impact “patient care and public health.”

Keep reading

Ohio Senate Committee Approves Bill To Allow Marijuana Sales From Dispensaries ‘Immediately’, Keep Home Grow And Expunge Records

In a stunning reversal, an Ohio GOP-controlled Senate committee has unanimously approved a revised bill that in many ways would expand the voter-approved marijuana legalization law that goes into effect on Thursday— by allowing adults to start buying marijuana from existing medical cannabis dispensaries in as soon as 90 days, maintaining home cultivation rights and providing for automatic expungements of prior marijuana convictions, among other changes.

Just days after the Senate General Government Committee advanced legislation to fundamentally undo key provisions of the cannabis initiative voters passed at the ballot last month—proposing to eliminate the home grow option and delaying legalization for at least one year until adult-use retailers started sales, for example—the panel dramatically walked back the measure and passed it in a unanimous bipartisan voice vote on Wednesday.

It’s now been referred to the Senate Rules and Reference Committee before potentially advancing to the floor as early as Wednesday evening. That said, it is not clear that the House is ready to make any changes on an expedited basis to the legalization measure that’s set to take effect on Thursday.

The overhaul of the measure comes one day after the Senate panel held a hearing and received public testimony on the initial proposal, with many advocates and stakeholders expressing frustration with the seeming undermining of voters’ decision and recommending changes such as freeing up medical cannabis dispensaries to start servicing adult consumers while regulators develop rules to license recreational retailers.

Sen. Rob McColley (R) detailed the latest changes following negotiations during an extensive recess in committee on Wednesday, stating that lawmakers’ focus “needs to be stamping out the black market” and also “protecting the access that the people of Ohioans voted for,” while ensuring that the administrative implementation “runs as efficiently as it possibly can, while protecting opportunities for for Ohioans to engage in this new industry.”

Committee Chairman Michael Rulli (R) said that over “the last three or four days, a lot of the public has reached out to probably every single one of our senators with thousands of emails and hundreds and hundreds and hundreds of calls.”

“I think the people have spoken,” he said.

Keep reading

DEA Threatens Georgia Pharmacies Over Dispensing Medical Marijuana Under State Law

Georgia recently became the first U.S. state to allow pharmacies to sell medical marijuana, with nearly 120 facilities applying to sell cannabis oil as of October. But now the federal Drug Enforcement Administration (DEA) is warning pharmacies that dispensing THC is unlawful because it remains a Schedule I drug.

“All DEA registrants, including DEA-registered pharmacies, are required to abide by all relevant federal laws and regulations,” says a copy of a letter sent to a Georgia pharmacy by Matthew J. Strait, a DEA deputy assistant administrator in the agency’s Diversion Control Division. “A DEA-registered pharmacy may only dispense controlled substances in Schedules II-V of the Controlled Substances Act. Neither marijuana nor THC can lawfully be possessed, handled, or dispensed by any DEA-registered pharmacy.”

The letter, dated November 27, was first posted online by Smart Approaches to Marijuana (SAM), an anti-cannabis advocacy group. DEA did not immediately respond to emails from Marijuana Moment attempting to confirm its authenticity.

One potential complicating factor around DEA’s advisory is a congressional budget rider that prevents the the Department of Justice from spending resources to interfere with the implementation of state medical marijuana laws. The provision was first enacted into law in 2014 and was extended last month to at least February 2024.

It’s not immediately clear how DEA squares its threat against state-authorized pharmacies that provide medical cannabis oil to patients with the agency’s obligation to follow the congressionally enacted federal law.

Keep reading